Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats

Pharmaceutical Research

Volumn 15, Issue 11, 1998, Pages 1792-1795

  Chiou, Win L ^a   Barve, Abhijit ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Humans; Inter species; Oral absorption; Rats

Indexed keywords

CAFFEINE; CAMAZEPAM; CARFECILLIN; CEFADROXIL; CIMETIDINE; CISAPRIDE; CLOFIBRATE; DICLOFENAC; DRUG; ETHINYLESTRADIOL; FELODIPINE; FENCLOFENAC; GRANISETRON; IMIPRAMINE; KETOPROFEN; KETOROLAC; LEVODOPA; MORPHINE; NIZATIDINE; OXATOMIDE; PARACETAMOL; PHENAZONE; PROGESTERONE; SACCHARIN; SALICYLIC ACID;

ARTICLE; CORRELATION FUNCTION; DRUG ABSORPTION; DRUG CLEARANCE; FOOD AND DRUG ADMINISTRATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE;

ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHYSICAL; HUMANS; INTESTINAL ABSORPTION; LINEAR MODELS; PHARMACOKINETICS; RATS; SPECIES SPECIFICITY; THERAPEUTIC EQUIVALENCY;

EID: 0031786518     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011981317451     Document Type: Article

References (18)

1. G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
2. U. Fagerholm, M. Johansson, and H. Lennernäs. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1336-1342 (1996).
3. W. L. Chiou. Determination of drug permeability in a flat or distended stirred intestine: Prediction of fraction dose absorbed in humans after oral administration. Int. J. Clin. Pharmacol. Ther. 32:474-482 (1994).
4. W. L. Chiou. The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. Biopharm. Drug. Disp. 16:71-75 (1995).
5. M. E. Dowty and C. R. Dietsch. Improved prediction of in vivo peroral absorption from in vitro intestinal permeability using an internal standard to control for intra- and inter-rat variability. Pharm. Res. 14:1792-1797 (1997).
6. N. Takamatsu, L. S. Welage, N. M. Idkaidek, D. Liu, P. I-Der Lee, Y. Hayashi, J. K. Rhie, H. Lennernäs, J. L. Barnett, V. P. Shah, L. Lesko, and G. L. Amidon. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm. Res. 14:1127-1132 (1997).
7. P. Artursson and J. Karlsson. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880-885 (1991).
8. P. Artursson, K. Palm, and K. Luthman. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Advanced Drug Delivery Reviews 22:67-84 (1996).
9. P. Artursson and R. Borchardt. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14:1655-1658 (1997).
10. W. L. Chiou. The author replies to Lennernäs et al. J. Pharmacokin. Biopharm. 23:323-331 (1995).
11. W. L. Chiou. New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. J. Pharmacokin. Biopharm. 24:433-442 (1996).
12. M. G. Lee and W. L. Chiou. Studies on potential factors affecting incomplete absorption of furosemide: Gastric first-pass effect. J. Pharmacokin. Biopharm. 11:623-640 (1983).
13. F. H. Hsu, T. Prueksaritanont, M. G. Lee, and W. L. Chiou. The phenomenon and cause of dose-dependent oral absorption of chlorothiazide in rats: Extrapolation to human data based on the body surface area concept. J. Pharmacokin. Biopharm. 15:369-383 (1987).
14. L. Z. Benet, S. Øie, and J. B. Schwartz. Design and Optimization of dosage regimens; Pharmacokinetic data. In A. Goodman Gilman, J. G. Hardman, L. E. Limbard, P. B. Molinoff, and R. W. Ruddon (eds.) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition, pp. 1707-1792, McGraw Hill, NY, 1996.
15. S. Chong, S. A. Dando, K. M. Soucek, and R. A. Morrison. In vitro permeability through Caco-2 cells is not quantitatively predictive of in vivo absorption for peptide-like drugs absorbed via the dipeptide transporter system. Pharm. Res. 13:120-123 (1996).
16. A. Strocchi, G. Corazza, J. Furne, C. Fine, A. DiSario, G. Gasbarrini, and M. D. Levitt. Measurements of the jejunal unstirred layer in normal subjects and patients with celiac disease. Am. J. Physiol. 270:G487-G491 (1996).
17. Y. L. He, S. Murby, G. Warhurst, L. Gifford, D. Walker, J. Ayrton, R. Eastmond, and M. Rowland. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J. Pharm. Sci. 87:626-633 (1998).
18. D. C. Taylor, R. Grundy, and B. Loveday. Chronic dog intestinal loop model for studying drug absorption as exemplified by beta-adrenoceptor blocking agents, atenolol and propranolol. J. Pharm. Sci. 70:516-21 (1981).